Sanofi, Regeneron get FDA breakthrough therapy status for Dupixent to treat eosinophilic esophagitis

This article was originally published here

Dupixent, a fully-human monoclonal antibody, blocks the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. The regulator has provided breakthrough therapy device designation based on data from

The post Sanofi, Regeneron get FDA breakthrough therapy status for Dupixent to treat eosinophilic esophagitis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply